Moderna Shares Fall on Melanoma Vaccine Data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- BBC reported that a personalised cancer vaccine cut the risk of disease returning in a major trial; The New York Times described it as first-of-its-kind and a source of new hope for cancer patients.
- Moderna's shares fell as investors digested melanoma vaccine trial data; Yahoo Finance described the stock as trimming losses.
Why it matters: For cancer patients, the reported clinical claim is a reduction in recurrence risk from a vaccine The New York Times described as first-of-its-kind; for Moderna shareholders, the immediate market consequence was negative, with Yahoo Finance reporting trimmed losses as investors digested melanoma-vaccine trial data. One trial therefore carried both medical hope and an adverse stock reaction.
Ask SkimNews
